0001209191-19-036279.txt : 20190611
0001209191-19-036279.hdr.sgml : 20190611
20190611212234
ACCESSION NUMBER: 0001209191-19-036279
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190529
FILED AS OF DATE: 20190611
DATE AS OF CHANGE: 20190611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GONZALEZ DINA
CENTRAL INDEX KEY: 0001778684
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36278
FILM NUMBER: 19892328
MAIL ADDRESS:
STREET 1: C/O ADYNXX, INC.
STREET 2: 100 PINE ST., STE. 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adynxx, Inc.
CENTRAL INDEX KEY: 0001054274
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 582349413
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 PINE ST., STE. 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
BUSINESS PHONE: (415) 512-7740
MAIL ADDRESS:
STREET 1: 100 PINE ST., STE. 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
FORMER COMPANY:
FORMER CONFORMED NAME: Alliqua BioMedical, Inc.
DATE OF NAME CHANGE: 20140610
FORMER COMPANY:
FORMER CONFORMED NAME: Alliqua, Inc.
DATE OF NAME CHANGE: 20101222
FORMER COMPANY:
FORMER CONFORMED NAME: HEPALIFE TECHNOLOGIES INC
DATE OF NAME CHANGE: 20030529
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2019-05-29
0
0001054274
Adynxx, Inc.
ADYX
0001778684
GONZALEZ DINA
C/O ADYNXX, INC.
100 PINE ST., STE. 500
SAN FRANCISCO
CA
94111
0
1
0
0
CONTROLLER
Stock Option (Right to Buy)
1.11
2021-08-18
Common Stock
7966
D
Stock Option (Right to Buy)
1.11
2022-03-07
Common Stock
1577
D
Stock Option (Right to Buy)
1.39
2022-07-16
Common Stock
3155
D
Stock Option (Right to Buy)
1.39
2022-12-17
Common Stock
1577
D
Stock Option (Right to Buy)
3.06
2026-12-15
Common Stock
26358
D
On August 19, 2011, Reporting Person was granted an option to purchase 221,888 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.04 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,966 shares of the Issuer's common stock at a per share exercise price of $1.11. This option has fully vested.
Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding.
On March 8, 2012, Reporting Person was granted an option to purchase 43,936 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.04 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 1,577 shares of the Issuer's common stock at a per share exercise price of $1.11. This option has fully vested.
On July 17, 2012, Reporting Person was granted an option to purchase 87,873 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,155 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested.
On December 18, 2012, Reporting Person was granted an option to purchase 43,937 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 1,577 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested.
On December 16, 2016, Reporting Person was granted an option to purchase 734,212 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 26,358 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable.
Exhibit 24 - Power of Attorney
/s/ John McKenna, Attorney-in-Fact
2019-06-11
EX-24.3_859303
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS
Know all by these presents, that the undersigned hereby makes, constitutes and
appoints Rick Orr, John McKenna and Laura Berezin as the undersigned's true and
lawful attorney-in-fact, with full power and authority as hereinafter described
on behalf of and in the name, place and stead of the undersigned to:
(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including
any amendments thereto) with respect to the securities of Adynxx, Inc., a
Delaware corporation (the "Company"), with the SEC, any national securities
exchanges and the Company, as considered necessary or advisable under Section
16(a) of the Exchange Act and the rules and regulations promulgated thereunder,
as amended from time to time;
(2) seek or obtain, as the undersigned's representative and on the undersigned's
behalf, information on transactions in the Company's securities from any third
party, including brokers, employee benefit plan administrators and trustees, and
the undersigned hereby authorizes any such person to release any such
information to the undersigned and approves and ratifies any such release of
information; and
(3) perform any and all other acts which in the discretion of such
attorney-in-fact are necessary or desirable for and on behalf of the undersigned
in connection with the foregoing.
The undersigned acknowledges that:
(1) this Power of Attorney authorizes, but does not require, such
attorney-in-fact to act in their discretion on information provided to such
attorney-in-fact without independent verification of such information;
(2) any documents prepared and/or executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney will be in such form and will
contain such information and disclosure as such attorney-in-fact, in his or her
discretion, deems necessary or desirable;
(3) neither the Company nor such attorney-in-fact assumes (i) any liability for
the undersigned's responsibility to comply with the requirement of the Exchange
Act, (ii) any liability of the undersigned for any failure to comply with such
requirements, or (iii) any obligation or liability of the undersigned for profit
disgorgement under Section 16(b) of the Exchange Act; and
(4) this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under the Exchange Act,
including without limitation the reporting requirements under Section 16 of the
Exchange Act.
The undersigned hereby gives and grants the foregoing attorney-in-fact full
power and authority to do and perform all and every act and thing whatsoever
requisite, necessary or appropriate to be done in and about the foregoing
matters as fully to all intents and purposes as the undersigned might or could
do if present, hereby ratifying all that such attorney-in-fact of, for and on
behalf of the undersigned, shall lawfully do or cause to be done by virtue of
this Limited Power of Attorney.
This Power of Attorney shall remain in full force and effect until revoked by
the undersigned in a signed writing delivered to such attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 28th day of May 2019.
/s/ Dina Gonzalez
____________________________________
Dina Gonzalez